dc.contributor.author | Karadag, Ömer | |
dc.contributor.author | Kalyoncu, Umut | |
dc.contributor.author | Pehlivan, Yavuz | |
dc.contributor.author | Akar, Servet | |
dc.contributor.author | Kaşifoglu, Timuçİn | |
dc.contributor.author | Kimyon, Gezmİs | |
dc.contributor.author | Dalkilic, Hüseyİn Edİz | |
dc.contributor.author | Ertenli, Ali İhsan | |
dc.contributor.author | Kilic, Levent | |
dc.contributor.author | Ersözlü, Emine Duygu | |
dc.contributor.author | Bes, Cemal | |
dc.contributor.author | Emmungil, Hakan | |
dc.contributor.author | Mercan, Ridvan | |
dc.contributor.author | Ediboglu, Elİf | |
dc.contributor.author | Alpay Kanitez, Nilüfer | |
dc.contributor.author | Bilgin, Emre | |
dc.contributor.author | Çolak, Seda | |
dc.contributor.author | Koca, Süleyman Serdar | |
dc.contributor.author | Gönüllü, Emel | |
dc.contributor.author | Kücüksahİn, Orhan | |
dc.contributor.author | Nihan Coskun, Belkis | |
dc.contributor.author | Yagiz, Burcu | |
dc.contributor.author | Kiraz, Sedat | |
dc.date.accessioned | 2021-03-15T08:13:07Z | |
dc.date.available | 2021-03-15T08:13:07Z | |
dc.date.issued | 2021-02-22 | |
dc.identifier.citation | Kalyoncu U, Pehlİvan Y, Akar S, KaŞİfoĞlu T, Kİmyon G, KaradaĞ Ö, DalkiliÇ HE, Ertenlİ Aİ, KiliÇ L, ErsÖzlÜ ED, Bes C, Emmungİl H, Mercan R, EdİboĞlu E, Alpay Kanitez N, Bİlgİn E, Çolak S, Koca SS, GÖnÜllÜ E, KÜÇÜkŞahİn O, CoŞkun BN, YaĞiz B, Kİraz S. Preferences of Inflammatory Arthritis Patients for Biological Disease-Modifying Antirheumatic Drugs in the First 100 Days of COVID-19 Pandemic. Turk J Med Sci. 2021 Feb 22. doi: 10.3906/sag-2012-5. Epub ahead of print. PMID: 33611869. | tr_TR |
dc.identifier.issn | 1303-6165 | |
dc.identifier.uri | https://pubmed.ncbi.nlm.nih.gov/33611869/ | |
dc.identifier.uri | http://hdl.handle.net/11655/23546 | |
dc.identifier.uri | https://doi.org/10.3906/sag-2012-5 | |
dc.description.abstract | To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of COVID-19 pandemic. Method: A total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6-9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated and 1394 (74.5%) responded the survey performed by phone call. Patients? data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired for the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results: A total of 1,394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had polymerase chain reaction (PCR) confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p=0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21-73] vs. 44 years [20-79]; p=0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion: Although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. Long-term effects of the pandemic should be monitored. | tr_TR |
dc.language.iso | en | tr_TR |
dc.publisher | Turk J Med Sci | tr_TR |
dc.relation.isversionof | 10.3906/sag-2012-5 | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | tr_TR |
dc.subject | spondyloarthritis | tr_TR |
dc.subject | rheumatoid arthritis | tr_TR |
dc.subject | biologic DMARDs | tr_TR |
dc.subject | COVID-19 | tr_TR |
dc.title | Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of covid-19 pandemic | tr_TR |
dc.type | info:eu-repo/semantics/article | tr_TR |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Turk J Med Sci | tr_TR |
dc.contributor.department | İç Hastalıkları | tr_TR |
dc.identifier.volume | Epub ahead of print | tr_TR |
dc.identifier.startpage | 1 | tr_TR |
dc.identifier.endpage | 22 | tr_TR |
dc.description.index | PubMed | tr_TR |
dc.funding | TÜBİTAK | tr_TR |